Licensing status

Publication and contact information

Drug platforms

Reprogramming in vivo to generate totipotent induced pluripotent stem (iPS) cells

In vivo reprogramming in mice could be used to generate highly plastic iPS cells that can efficiently contribute to extraembryonic tissue such as placenta. Mice were engineered to express four doxycycline-inducible reprogramming factors: Oct4, Sox2, Klf4 and c-Myc (Myc). In these mice, doxycycline led to the formation of iPS cells in multiple organs that originated from multiple cell types. The in vivo-generated iPS cells were more efficient at forming embryonic and extraembryonic tissues than embryonic stem cells or in vitro-generated iPS cells. Next steps include understanding the mechanism of in vivo reprogramming and why the resulting iPS cells show greater totipotency than other stem cell lines.

SciBX 6(42); doi:10.1038/scibx.2013.1206
Published online Oct. 31, 2013

Patent application filed; available for licensing through the Botín Foundation
Contact: Miriam Zeini, Botín Foundation, Madrid, Spain

Abad, M. et al. Nature;
published online Sept. 11, 2013;
Contact: Manuel Serrano, Spanish National Cancer Research Centre (CNIO), Madrid, Spain